An observational study in Asthma, sponsored by Sanofi. Completed at 41 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Sanofi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.
Among the 37 studies in Asthma by Sanofi, this one is one of 3 that started in 2020, is one of 5 observational ones, and was the 23rd registered.
4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Canada, France and 3 more countries
Ages 6+
Sanofi · Sites in United States, Argentina, Belgium and 18 more countries
Ages 18+
Sanofi · Sites in United States, Argentina, Brazil and 13 more countries
Ages 2–5
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 376 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 450 across the 31 interventional studies, 144 across the 5 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Asthma by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06676319SanofiStudy of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Asthma by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment history, socio-demographic, biomarkers (including Fractional exhaled nitric oxide [FeNO]), and concomitant treatments for asthma.
Secondary Objectives:
The secondary objectives of the study are:
Each patient will be followed for up to 36 months.
Patients with asthma initiating DUPIXENT for their asthma according to the prescribing information in effect in each country.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country
Drug: Dupilumab SAR231893
Pharmaceutical form:solution Route of administration: subcutaneous Dose regimen:
Also known as: Dupixent
Baseline Characteristics: Socio-demographics
Socio-demographics including but not limited to gender, age, race, weight, and height
Time frame: At baseline
Baseline Characteristics: Medical history
Including asthma history and asthma treatment history
Time frame: At baseline
Baseline Characteristics: Disease characteristics
Disease characteristics including asthma, comorbid conditions, family history and history of inflammatory diseases
Time frame: At baseline
Baseline Characteristics: Biomarkers
Including fractional exhaled nitric oxide (FeNo), blood eosinophils count, immunoglobulin E (IgE total/specific)
Time frame: At baseline
Baseline Characteristics: Concomitant treatments for asthma
Time frame: At baseline
Dupixent and other asthma treatment use patterns
Including doses and dose frequency, treatment duration, asthma treatment associations (eg, Dupixent monotherapy, Dupixent + inhaled corticosteroids (ICS), Dupixent + ICS + additional controllers, oral corticosteroid (OCS) burst), and reasons for initiation and for discontinuation/switching.
Time frame: Baseline to Month 36
Lung function
Pre and post bronchodilator (BD) forced expiratory volume in 1 second (FEV1) over time.
Time frame: Baseline to Month 36
Annualized exacerbation rate
A severe exacerbation event is defined as a deterioration of asthma requiring: * Use of systemic corticosteroids for ≥3 days; or * Hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.
Time frame: Baseline to Month 36
Patient reported outcomes: Asthma Control Questionnaire (6-item) (ACQ-6)
To evaluate asthma control
Time frame: Baseline to Month 36
Patient reported outcomes: Patient Oriented Eczema Measure (POEM) among participants with atopic dermatitis
Among participants with atopic dermatitis
Time frame: Baseline to Month 36
Patient reported outcomes: Allergic Rhinitis Visual Analogue Scale (AR-VAS) among participants with allergic rhinitis
Among participants with allergic rhinitis
Time frame: Baseline to Month 36
Patient reported outcomes: Sino-nasal Outcome Test (SNOT-22)
Among participants with chronic rhinosinusitis with nasal polyps \[CRSwNP\] and chronic rhinosinusitis \[CRS\] without nasal polyps \[NP\])
Time frame: Baseline to Month 36
Healthcare Resource Utilization
The Healthcare Resource Utilization (HCRU) collects information on unscheduled healthcare resource encounters including inpatient visits, emergency room visits, physician office visits related to asthma, including the dates of visits and duration of any hospitalizations, together with the reason for the visits
Time frame: Baseline to Month 36
Number of participants with adverse events (AE) and serious adverse events (SAE)
Time frame: Baseline to Month 36
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2020 to primary completion in Jun 2026, 67 months.
Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's 67 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.